---
title: "Sheel Biotech Ltd (SHEEL) — Share Price, Financials & Analysis"
symbol: "SHEEL"
company: "Sheel Biotech Ltd"
canonical: "https://tapetide.com/stocks/SHEEL"
isin: "INE0YJV01017"
nse_symbol: "SHEEL"
sector: "Services"
industry: "Commercial Services & Supplies"
market_cap_cr: 119.88
generated_at: "2026-09-13T18:51:22.359Z"
---

# Sheel Biotech Ltd (SHEEL)

Canonical page: https://tapetide.com/stocks/SHEEL

## Company

- **NSE Symbol:** SHEEL
- **ISIN:** INE0YJV01017
- **Sector:** Services
- **Industry:** Commercial Services & Supplies
- **Macro Sector:** Services
- **Stock Type:** EQUITY
- **Listed Since:** 2025-10-08
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** sheelbiotech.com

## About

Incorporated in November 1994, Sheel Biotech Limited specializes in biotechnology, floriculture, greenhouses, and organic projects.[1]

## Latest Price

- **Price:** ₹61
- **Change:** -1 (-1.61%)
- **Open:** ₹59.3
- **Day High:** ₹61
- **Day Low:** ₹58.9
- **Previous Close:** ₹62
- **Volume:** 16000
- **As Of:** 2026-09-11T08:54:38+00:00

## Key Fundamentals

Observed at 2026-09-11T04:44:46.233315Z.

- **Market Cap:** ₹119.88 Cr
- **Classification:** SME
- **P/E (reported):** 10.7
- **Book Value:** ₹62.4
- **Price to Book:** 0.99
- **Dividend Yield:** 0%
- **ROE:** 12.68%
- **ROCE:** 16.34%
- **Debt to Equity:** 0.2
- **Revenue (yearly):** ₹110.02 Cr
- **Net Income:** ₹11.59 Cr
- **EBITDA:** ₹16.28 Cr
- **52-Week High:** ₹95.55
- **52-Week Low:** ₹37.8
- **RSI (14):** 46.08

## Tapetide Score

- **Score:** 48 / 100
- **Score date:** 2026-09-04
- **Archetype:** Trend Ahead of Fundamentals
- **What it means:** The price trend is running ahead of what the financials currently support. Moves like this depend on the fundamentals catching up; check what would have to be true for that.
- **Pillar profile:** Quality: Average · Valuation: Expensive · Momentum: Rising
- **Percentile:** 39.4 (of 4473 scored stocks)
- **Confidence:** 88%
- **Data coverage:** 76%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 66.68 | 9% |
| growth | 44.13 | 9% |
| momentum | 76.8 | 12% |
| ownership | 47.52 | 24% |
| quality | 57.07 | 22% |
| valuation | 47.21 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company has delivered good profit growth of 20.1% CAGR over last 5 years

### Weaknesses

- The company has delivered a poor sales growth of 11.8% over past five years.
- Company has high debtors of 183 days.

## Growth Rates

| Metric | 1Y | 3Y | 5Y |
| --- | --- | --- | --- |
| cash flow growth | — | -0.86% | — |
| ebitda margin growth | -2.97% | -7.55% | 55.56% |
| net income growth | 9.34% | 32% | 20% |
| revenue growth | 7.55% | 7% | 12% |
| roce | -0.85% | 52% | 12.01% |
| roe | -12.01% | 11.69% | 49.88% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2024 | Sep 2025 |
| --- | --- | --- |
| Sales | 11 | 22 |
| Expenses | 14 | 20 |
| Operating Profit | -2 | 2 |
| OPM % | -22 | 8 |
| Other Income | 0 | 0 |
| Interest | 1 | 1 |
| Depreciation | 0 | 1 |
| Profit before tax | -4 | 0 |
| Tax % | 3 | 24 |
| Net Profit | -4 | 0 |
| EPS in Rs | -2.53 | 0.13 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- |
| Sales | 63 | 84 | 89 | 103 | 110 | 110 |
| Expenses | 56 | 78 | 80 | 89 | 95 | 94 |
| Operating Profit | 7 | 6 | 9 | 14 | 15 | 16 |
| OPM % | 10 | 8 | 10 | 14 | 14 | 15 |
| Other Income | 0 | 0 | 0 | 0 | 1 | 1 |
| Interest | 1 | 1 | 2 | 1 | 2 | 2 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 5 | 5 | 6 | 12 | 13 | 14 |
| Tax % | 0 | 2 | 20 | 15 | 17 | 16 |
| Net Profit | 5 | 5 | 5 | 10 | 11 | 12 |
| EPS in Rs | 11.58 | 10.88 | 12.26 | 25.27 | 7.12 | 5.78 |
| Dividend Payout % | 0 | 28 | 25 | 12 | 14 | 0 |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
| --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 4 | 4 | 4 | 4 | 15 | 15 |
| Reserves | 53 | 56 | 59 | 69 | 69 | 69 |
| Borrowings | 21 | 24 | 19 | 24 | 17 | 27 |
| Other Liabilities | 4 | 10 | 11 | 10 | 12 | 13 |
| Total Liabilities | 82 | 93 | 94 | 106 | 113 | 124 |
| Fixed Assets | 8 | 8 | 8 | 7 | 7 | 7 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 1 | 1 | 1 | 1 | 1 |
| Other Assets | 75 | 84 | 85 | 98 | 105 | 116 |
| Total Assets | 82 | 93 | 94 | 106 | 113 | 124 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | — | 2 | 9 | -1 | 9 | -18 |
| Cash from Investing Activity | — | -2 | -2 | 0 | -2 | -7 |
| Cash from Financing Activity | — | 0 | -7 | 2 | -7 | 26 |
| Net Cash Flow | — | 0 | 0 | 0 | 0 | 2 |
| Free Cash Flow | — | 1 | 8 | -1 | 8 | -24 |
| CFO/OP | — | 37 | 105 | 3 | 75 | -94 |

### Ratios

| Item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 352 | 280 | 230 | 204 | 182 | — |
| Inventory Days | 55 | 120 | 177 | 263 | 272 | — |
| Days Payable | 30 | 85 | 75 | 37 | 29 | — |
| Cash Conversion Cycle | 377 | 315 | 332 | 430 | 426 | — |
| Working Capital Days | 348 | 274 | 255 | 256 | 253 | — |
| ROCE % | — | 7 | 10 | 15 | 14 | — |

## Shareholding Pattern

### Quarterly

| Category | Sep 2025 | Mar 2026 |
| --- | --- | --- |
| Promoters | 96.99% | 72.3% |
| FIIs | 0% | 0% |
| DIIs | 0% | 9.49% |
| Government | 0% | 0% |
| Public | 0% | 10.89% |
| Others | 3.01% | 7.32% |
| No. of Shareholders | 33 | 395 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Sell
- **Buy / Neutral / Sell:** 1 / 7 / 11

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 61.07 | Sell |
| EMA (10) | 61.81 | Sell |
| SMA (20) | 63.52 | Sell |
| EMA (20) | 63.06 | Sell |
| SMA (50) | 65.91 | Sell |
| EMA (50) | 62.56 | Sell |
| SMA (100) | 55.47 | Buy |
| EMA (100) | 61.31 | Sell |
| SMA (200) | 62.89 | Sell |
| EMA (200) | 63.76 | Sell |

### Oscillators — summary: **Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 43.93 | Neutral |
| MACD (12,26,9) | -1.31 | Sell |
| Stochastic (14,3,3) | 35.84 | Neutral |
| ADX (14) | 21.93 | Neutral |
| Williams %R (14) | -63.08 | Neutral |
| ATR (14) | 2.31 | High Volatility |
| ROC (12) | -4.69 | Sell |
| Stoch RSI (14) | 62.79 | Neutral |
| UO (7,14,28) | 64.48 | Neutral |

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 9 Sep - Sheel Biotech Limited has informed regarding regarding Record Date & Book Closure for the purpose of 35th Annual General Meeting | [Updates 9 Sep - Sheel Biotech Limited has informed regarding regarding Record Date & Book Closure for the purpose of 35th Annual General Meeting](https://nsearchives.nseindia.com/corporate/SHEELBIOTECH_09092026160120_Intimation_RecordDate_BookClosure_.pdf) |
| 9 April 2026 - Sheel Biotech Limited has informed regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 | [Trading Window 9 April 2026 - Sheel Biotech Limited has informed regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015](https://nsearchives.nseindia.com/corporate/SHEELBIOTECH_09042026153005_Window_Closure_v1.pdf) |
| 9 April 2026 - Sheel Biotech Limited has informed regarding 'Non-Applicability of the Regulation 24A (Secretarial Compliance Report) of the SEBI (LODR) Regulations.' | [Updates 9 April 2026 - Sheel Biotech Limited has informed regarding 'Non-Applicability of the Regulation 24A (Secretarial Compliance Report) of the SEBI (LODR) Regulations.'](https://nsearchives.nseindia.com/corporate/SHEELBIOTECH_09042026153520_Sec_Comp_Report-Reg_24A_V1.pdf) |
| 8 July 2026 - Revised audited FY26 results filed; revenue Rs11,002.24 lakh, profit Rs1,175.64 lakh. | [Reply to Clarification- Financial results 8 July 2026 - Revised audited FY26 results filed; revenue Rs11,002.24 lakh, profit Rs1,175.64 lakh.](https://nsearchives.nseindia.com/corporate/SHEELBIOTECH_30062026171747_Reply_query_30-06-26_v2.pdf) |
| 8 April 2026 - Sheel Biotech Limited has informed regarding Resignation of Mr Anil Kumar as Chief Financial Officer of the company w.e.f. April 07, 2026. | [Resignation 8 April 2026 - Sheel Biotech Limited has informed regarding Resignation of Mr Anil Kumar as Chief Financial Officer of the company w.e.f. April 07, 2026.](https://nsearchives.nseindia.com/corporate/SHEELBIOTECH_08042026202158_Reg_30_CFO_-v1.pdf) |
| 7 April 2026 - Sheel Biotech Limited has informed regarding Submission of the Compliance Report on Corporate Governance for the Q-04 FY 2025-26. | [Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter 7 April 2026 - Sheel Biotech Limited has informed regarding Submission of the Compliance Report on Corporate Governance for the Q-04 FY 2025-26.](https://nsearchives.nseindia.com/corporate/SHEELBIOTECH_07042026141216_Reg_27_2__SBL_31-03-2026.pdf) |
| 7 April 2026 - Sheel Biotech Limited has informed about Certificate under SEBI (Depositories and Participants) Regulations, 2018 | [Certificate under SEBI (Depositories and Participants) Regulations, 2018 7 April 2026 - Sheel Biotech Limited has informed about Certificate under SEBI (Depositories and Participants) Regulations, 2018](https://nsearchives.nseindia.com/corporate/SHEELBIOTECH_07042026160540_SBL__reg_74_5_.pdf) |
| 7 April 2026 - Promoter of Sheel Biotech Limited has informed regarding 'Declaration under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. | [Updates 7 April 2026 - Promoter of Sheel Biotech Limited has informed regarding 'Declaration under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.](https://nsearchives.nseindia.com/corporate/SHEELBIOTECH_07042026181250_Declaration_31_4__page-0001.pdf) |
| 6 May 2026 - Compliance certificate for FY 2025-26 confirms SDD in place; nil noncompliance. | [Structural Digital Database 6 May 2026 - Compliance certificate for FY 2025-26 confirms SDD in place; nil noncompliance.](https://nsearchives.nseindia.com/corporate/SHEELBIOTECH_06052026161935_Final_SDD_SBL.pdf) |
| 5 June 2026 - Sheel Biotech Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, … | [Disclosure under SEBI Takeover Regulations 5 June 2026 - Sheel Biotech Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, …](https://nsearchives.nseindia.com/corporate/team_sandeshc_01062026151354_19.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Annual Report 2026 from nse](https://archives.nseindia.com/annual_reports/SME_AR_30950_SHEEL_2025_2026_A_5747201_31082026223149.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:51:22.359Z.